Teva CEO eyes partnerships with Indian pharma

Fresh off its acquisitions of U.S.-based Cephalon and Japan's Taiyo Pharmaceuticals, generics giant Teva Pharmaceutical Industries is casting about for partners in India. Globes news service reports that Teva chief Shlomo Yanai recently dropped in there on a scouting expedition for potential collaborations.

Late last year, the drugmaker said it was in the market for deals in India, China and Japan. Now that it has Taiyo in the bag, Teva can check Japan off that list. India and China obviously remain, but as Globes points out, swallowing its two recent acquisitions will take time and effort. So, collaborating with domestic drugmakers may be its preferred option.

Teva wouldn't comment on the report, but it was happy to announce its latest product--a generic version of the Alzheimer's drug Aricept that was launched yesterday in the U.S. The company says sales of branded and generic versions of the drug amount to $2.3 billion. Of course, it will have to compete with a slew of other copycat drugmakers for a share of that market; fellow Indian generics makers Aurobindo Pharma, Sun Pharma and others are among those with FDA approval.

- see the release from Teva
- get the Globes news
- read the PharmaTimes story

Suggested Articles

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.

ICER said that Vertex's triplet CF therapy Trikafta would only be cost effective if the price were dropped from $311,000 to no more than $85,500.